Does machine learning work on DEL datasets? Indeed it does. Sometimes. pubs.acs.org/doi/10.1021/ac…

A charismatic leader. Economic malaise. Enemies within. Expert propaganda. Angry young men. Demonization of “others”. And voted into power. We’ve seen this script before. C’mon America, we don’t want to watch the sequel.

Canada and Toronto are great places to go to grad school or to do a post-doc. Just saying.

Neuroscientist Carl Laflamme describes YCharOS, an initiative testing commercial antibodies to determine if they work as advertised, and making findings open to improve research efficiency and reproducibility. via nature buff.ly/40AgsNn #OpenScience

Steve Kerr on the election Kerr: “I believe in democracy. I think the American people have spoken and voted for Trump. I want him to do well the next four years. I want our country to do well.” Kerr (sarcastically): “I'm just thankful there wasn't any voting fraud this time.

Draining the swamp. Assessment of 614 commercial antibodies, targeting a total of 65 neuroscience-related proteins, demonstrated two thirds of them did not work as recommended by manufacturers. Don’t trust, validate aled edwards nature.com/articles/d4158…

Trump got fewer total votes this election than last. 12 million (!!) Democrats just didn’t show up and vote this time. It would have been landslide Harris victory if they had.

Congrats to Structural Genomics Consortium (SGC) Board member, Dafydd Owen 🏴󠁧󠁢󠁷󠁬󠁳󠁿, for leading the team that invented the active ingredient in Paxlovid, which was awarded a #PrixGalien prize last night!

It’s very encouraging that funders support projects like YCharOS, which does not address hypotheses, but rather does the foundational, but not sexy, work of testing and characterizing reagent antibodies in order to make everyone else’s science more robust and reproducible.

Just Launched! Episode 1 of the Target 2035 Podcast Series🎧 In the debut episode, Rachel Harding welcomes Cheryl Arrowsmith, a leading scientist in chemical biology and one of the initiators of Target 2035. podcasters.spotify.com/pod/show/targe… #Target2035 #OpenScience #DrugDiscovery

#AlphaFold3 is open-source for academic use now! See what our partner, Mohammed AlQuraishi, has to say about our upcoming OpenFold3 project and commercial availability. #BioAI #OpenSource #OpenFold nature.com/articles/d4158…

Want to be a fly on the wall in an industry-standard drug discovery program? Join the M4K Pharma monthly zooms. Real pros at work, sharing their expertise to try to invent an open source medicine to treat children’s brain tumours.

The Unites States government is now going to do the grand experiment to test if those loud and opinionated armchair athletes and coaches have what it takes when given the chance to lead the team. I don’t think it’s going to be pretty.

This WD paper reports machine learning applied to DNA-encoded library screening datasets at scale. Bottom line it works. Sometimes. Lots of opportunities to improve. Including by open sourcing models as James has done here. chemrxiv.org/engage/chemrxi…

Save the date for the second annual Conscience Symposium on Open Drug Discovery! Join us in Montreal on April 7-8, 2025, for two days dedicated to advancing open and AI-driven drug discovery. Learn more: conscience.ca/event/save-the…

A news feature by nature addresses the longstanding issue of unreliable antibodies in biomedical research and highlights the efforts of initiatives like YCharOS. A piece worth reading featuring the amazing work by Carl Laflamme's group: nature.com/articles/d4158…

A well anticipated overview highlighting the first CACHE challenge, which brought together 23 research teams from 10 countries to collectively predict 1,955 compounds targeting LRRK2-a protein linked to #ParkinsonsDisease. pubs.acs.org/doi/10.1021/ac…

I am outta here. See you at aled edwards.bsky.social